✦ LIBER ✦

A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors

✍ Scribed by Wakui, Hiroshi; Yamamoto, Noboru; Kitazono, Satoru; Mizugaki, Hidenori; Nakamichi, Shinji; Fujiwara, Yutaka; Nokihara, Hiroshi; Yamada, Yasuhide; Suzuki, Kohei; Kanda, Hironori; Akinaga, Shiro; Tamura, Tomohide

Book ID: 125344308
Publisher: Springer
Year: 2014
Tongue: English
Weight: 366 KB
Volume: 74
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-014-2467-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I, dose-escalation study of the

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

✍ Hollebecque, A.; Deutsch, E.; Massard, C.; Gomez-Roca, C.; Bahleda, R.; Ribrag, 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 445 KB

A Phase I, dose-finding and pharmacokine

A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors

✍ Noboru Yamamoto; Hiroshi Nokihara; Yasuhide Yamada; Yasushi Goto; Maki Tanioka; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB

Safety and tolerability of AZD8055 in Ja

Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study

✍ Asahina, Hajime; Nokihara, Hiroshi; Yamamoto, Noboru; Yamada, Yasuhide; Tamura, 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 317 KB

Phase I dose-escalation study of the HSP

Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors

✍ Toshihiko Doi,Yusuke Onozawa,Nozomu Fuse… 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 733 KB

Erratum to: Safety and tolerability of A

Erratum to: Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study

✍ Asahina, Hajime; Nokihara, Hiroshi; Yamamoto, Noboru; Yamada, Yasuhide; Tamura, 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 187 KB

Phase 1 and dose-finding study of patrit

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors

✍ Wakui, Hiroshi; Yamamoto, Noboru; Nakamichi, Shinji; Tamura, Yousuke; Nokihara, 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 341 KB